Chronic Pancreatitis, Pancreatic Cysts, and Pancreatic Neoplasms: Chronic Pancreatitis and Cysts: Late Complications

0:00Welcome to Board Pearls. This is episode two of five of the Chronic Pancreatitis, Pancreatic Cysts, and Pancreatic Neoplasms chapter, in the Pancreatic and Biliary Disease module. This episode is what the scarred gland stops making, and the other ways it causes trouble. The first patient is the man from episode one, now with greasy stools and a high glucose, and his case shows why steatorrhea appears late, how enzymes are dosed and why timing matters, what to do when they don't work and how to judge them, and what makes type three c diabetes different and dangerous. The second patient is a woman with a collection behind her stomach, and her case shows the complications of chronic pancreatitis over several years, each managed by its anatomy: the pseudocyst, the disconnected duct, the fibrotic bile duct stricture, splenic vein thrombosis with gastric varices, high-amylase ascites, and the long-term cancer risk.

0:57Here's the first patient. He's the forty-nine-year-old man with alcohol- and tobacco-related chronic pancreatitis, a calcified gland, and a dilated duct, whose pain is much better after a lateral pancreaticojejunostomy. He has four or five pale, greasy, foul-smelling stools a day that are hard to flush, and he's lost seven kilograms over a year, with a body mass index, BMI, of twenty. His fecal elastase is forty-five micrograms per gram, his hemoglobin A1c is seven point four, and his C-peptide is low. He's stopped drinking and is cutting down on cigarettes.

1:32His greasy stools, weight loss, and elastase of forty-five mean exocrine pancreatic insufficiency, and his low C-peptide and raised A1c mean pancreatogenic diabetes. Both appeared late for the same reason. The pancreas has a large functional reserve, so steatorrhea, weight loss, and deficiency of vitamins A, D, E, and K appear only after exocrine function falls below about ten percent of normal. Modest injury makes function tests abnormal without causing clinical malabsorption, while clinical malabsorption means advanced loss of the gland. His steatorrhea, weight loss, and elastase below one hundred mean less than a tenth of his exocrine function remains. A patient with normal stools, stable weight, and an elastase above that cutoff would have modest injury, followed over time.

2:21Before treatment, he has a baseline bone density scan and vitamin levels, because his malabsorption threatens more than his weight. Vitamin D malabsorption plus the bone turnover of smoking drive a high prevalence of bone disease in chronic pancreatitis, and enzymes started early may help prevent or reverse it. His fat-soluble vitamins are checked, and so is his B12, because exocrine insufficiency impairs the cleavage of B12 from its R-protein complex in the duodenum.

2:47His treatment is pancreatic enzyme replacement therapy, PERT, given with food, because lipase needs a meal to act on. The starting dose is forty thousand to fifty thousand United States Pharmacopeia, USP, lipase units with each main meal and half that, ten thousand to twenty-five thousand, with snacks, titrated up to ninety thousand USP per meal. One international unit equals three USP units, so a reference quoting international units shows a number a third as large: his fifty thousand USP is about seventeen thousand international units, and fifty thousand international units would be three times his dose, beyond the ninety thousand USP ceiling. Exogenous lipase, protease, and amylase replace his missing output, and taking them before or after meals separates the enzyme from the food it's meant to digest.

3:41His first response isn't enough. Six weeks later he still has three greasy stools a day, and his weight hasn't changed. The steps for a poor response are to check adherence, confirm the enzymes are taken with meals, raise the dose, add a proton pump inhibitor, PPI, and exclude other causes of diarrhea: small intestinal bacterial overgrowth, SIBO, bile acid malabsorption, celiac disease, and mucosal disease. A PPI helps because gastric acid inactivates non-coated lipase, and even enteric-coated microspheres need a near-neutral duodenal pH for the coating to dissolve and release the enzyme in time.

4:21His history shows why timing is checked before the dose. He's been taking his capsules first thing in the morning and at bedtime with his other pills, so his timing is fixed before anything else, and his stools improve. With perfect timing and adherence, the dose would rise toward ninety thousand with a PPI, and failure beyond that would prompt a search for SIBO or bile acid diarrhea rather than more enzyme.

4:46His response is judged clinically, because the lab test can't tell the enzymes apart. A repeat fecal elastase doesn't reliably separate replacement enzyme from his own, so response is titrated by weight, stool consistency, fat-soluble vitamin levels, and fecal fat measurement when needed. Symptoms alone are unreliable, because a patient can feel better while still malabsorbing fat, so his weight is checked at every visit and his vitamin levels are measured.

5:13His diabetes is a different disease from type two, and the difference makes it dangerous. The American Diabetes Association recognizes type three c, or pancreatogenic, diabetes as distinct from type two. The same fibroinflammatory injury that destroyed his acini destroys the islets: the beta cells that make insulin, the alpha cells that make glucagon, and the pancreatic polypeptide cells. So counter-regulatory glucagon is lost along with insulin, and hypoglycemia is brittle, severe, and unpredictable, because the normal glucagon rescue from a low glucose is gone. Type three c is recognized by a lower BMI, a low C-peptide from beta-cell loss rather than insulin resistance, no features of metabolic syndrome, and exocrine insufficiency on the same workup, and he has all four. A BMI of thirty-six, a high C-peptide, hypertension, fatty liver, and a normal elastase would mean type two diabetes, even with chronic pancreatitis.

6:14That loss of glucagon changes how his diabetes is treated. Insulin is titrated conservatively, because no glucagon corrects an overshoot. Sulfonylureas add hypoglycemia risk without addressing the insulin deficiency. Metformin is a reasonable adjunct and may modestly reduce cancer risk. Glucagon-like peptide one receptor agonists are typically avoided after pancreatitis, because their use after an attack carries an unresolved risk of recurrence, and he's had two attacks. He starts metformin, with low-dose insulin titrated slowly and hypoglycemia teaching if he needs it.

6:49The second patient shows the structural complications of chronic pancreatitis, which unfold over years. A fifty-six-year-old woman has alcohol-related chronic pancreatitis with calcifications in her pancreatic head and stopped drinking a year ago. For a month she's had early fullness and vomiting after meals. Her computed tomography, CT, shows a seven-centimeter round, well-walled fluid collection behind her stomach, compressing it, without solid debris. Her last acute attack was four months ago.

7:19A mature, well-walled fluid collection without debris, four months after an attack and compressing her stomach, is a symptomatic pseudocyst. Pseudocysts occur in about twenty-five percent of patients with chronic pancreatitis, most often alcohol-related: mature peripancreatic fluid collections with a fibrous wall that lacks an epithelial lining, forming at least four weeks after an acute episode or from duct disruption in established disease. Asymptomatic pseudocysts are observed regardless of size, because most resolve over weeks to months and the risk of drainage exceeds the risk of waiting. Symptomatic pseudocysts, causing pain, gastric outlet obstruction, or biliary obstruction, are drained, as are infected or rapidly enlarging ones. Hers is causing gastric outlet obstruction, so she needs drainage.

8:08Her drainage is endoscopic, after one safety check. The preferred approach for a mature collection is endoscopic ultrasound, EUS, guided cyst-gastrostomy or cyst-duodenostomy with a lumen-apposing metal stent, LAMS. Its flanges hold the cyst and gut walls together, and its ten-to-twenty-millimeter lumen lets debris out and allows direct necrosectomy if needed. It matches surgical cyst-gastrostomy in efficacy with a shorter hospital stay, with long-term success of seventy to ninety-five percent and complications in five to thirty-five percent, the higher end in walled-off necrosis. Before any drainage, a pseudoaneurysm, most often of the gastroduodenal or splenic artery, is considered, and it's suspected with bleeding, a suddenly enlarging collection, or an unexplained fall in hemoglobin, and embolized first. Her hemoglobin is stable, she has a LAMS cyst-gastrostomy, her vomiting stops, and the stent is removed weeks later.

9:08Her pseudocyst then comes back, and the recurrence itself is the clue. Three months after her stent comes out, the collection re-forms in the same place, which raises disconnected duct syndrome. In that syndrome, the pancreatic duct is severed, separating a viable distal segment from drainage into the duodenum, so the distal gland keeps secreting into a space with no exit, and once a temporary stent is removed, the tract collapses and fills again. A disconnected duct needs permanent transmural drainage with long-term plastic stents, or surgical resection of the disconnected segment, with magnetic resonance cholangiopancreatography, MRCP, defining the anatomy first. Her MRCP shows her duct cut off in the body with a viable tail, so she's drained again with plastic stents left in long term.

9:57Transpapillary stenting, through the papilla, suits a different problem. It's reserved for pseudocysts that communicate with an intact duct, for duct disruption with pancreatic ascites or a fistula, and for pseudocysts with duct strictures or stones, because bridging a leak in a continuous duct lets it heal. A disconnected duct has no continuity to bridge.

10:17Her fibrosis later reaches her bile duct. A year later her alkaline phosphatase is three times normal and her bilirubin two point five, with a long, smooth narrowing of the distal common bile duct through her pancreatic head and no mass. She has a distal bile duct stricture from fibrosis around the pancreatic head, which presents with progressive cholestasis. It's treated with a fully covered self-expanding metal stent left for six to twelve months, and removed before it embeds, or with biliary bypass surgery. Calcification in the pancreatic head lowers endoscopic success, because a fibrocalcific stricture doesn't reliably yield to dilation, so surgery may follow. Cancer is excluded before the stricture is called benign, as chapter twenty-seven covers.

11:03Her inflammation also reaches her splenic vein. Two years in, she vomits blood from fundal varices, with no esophageal varices, normal liver tests, no cirrhosis, a thrombosed splenic vein, and a large spleen. Splenic vein thrombosis from peripancreatic inflammation causes isolated gastric varices and sinistral, or left-sided, portal hypertension, because blood leaving the spleen is diverted backward through the short gastric veins into the fundus. Once the bleeding is controlled, splenectomy is curative, because it removes the high-flow inlet to the blocked segment, a different mechanism from the generalized portal hypertension of cirrhosis. Anticoagulation is reserved for clot that extends into the portal or superior mesenteric vein, so her clot, confined to the splenic vein, isn't anticoagulated.

11:53A leaking duct can also fill the abdomen or the chest. Pancreatic ascites and pleural effusions come from a disconnected duct or a ductal fistula leaking into the peritoneum, or into the retroperitoneum and up into the chest. A markedly raised fluid amylase confirms a pancreatic source rather than liver or heart failure. Treatment is a transpapillary stent across the leak, or transmural drainage of a disconnected segment.

12:18Her disease also carries long-term risks that shape her follow-up. After necrotizing pancreatitis, exocrine insufficiency affects about twenty-five percent of patients, and diabetes is twice as likely as in the general population. The lifetime pancreatic cancer risk across chronic pancreatitis is about four percent, a standardized incidence ratio of about twenty-three, and it's highest in PRSS1 hereditary pancreatitis and in smokers. Routine cancer surveillance isn't recommended in non-hereditary chronic pancreatitis, so her alcohol-related disease brings no screening program, though cancer stays in mind with any new stricture.

12:57Here are the traps the boards set in insufficiency and diabetes. Steatorrhea isn't expected in mild disease. Bone density and B12 are checked at baseline. Enzymes aren't started too low, and international units aren't confused with USP units. Enzymes are taken with meals, and timing and adherence are checked before the dose is raised. A PPI is added for a poor response. Repeat fecal elastase doesn't judge response. A lean patient with a low C-peptide and exocrine insufficiency has type three c diabetes, not type two. And type three c diabetes isn't treated with a sulfonylurea, aggressive insulin titration, or a GLP-1 agonist after pancreatitis.

13:40For the complications, the traps are these. An asymptomatic pseudocyst isn't drained because it's large. EUS drainage is preferred over surgery for a mature collection. A pseudoaneurysm is considered before any drainage. Stents in a disconnected duct aren't removed with the expectation that the collection stays closed, and a transpapillary stent doesn't treat it. A calcified head stricture often won't stay open after dilation. Isolated gastric varices with a normal liver are cured by splenectomy, not treated as cirrhosis. A clot confined to the splenic vein isn't anticoagulated. High-amylase ascites means a duct leak. And cancer isn't screened for in non-hereditary disease.

14:24So, start to finish. Clinical malabsorption means less than ten percent of exocrine function remains, so check bone density, vitamins, and B12. Give PERT with meals, forty thousand to fifty thousand USP lipase units per meal and half with snacks, up to ninety thousand, and for a poor response check timing and adherence, raise the dose, add a PPI, and look for SIBO, bile acid diarrhea, or celiac disease. Judge response by weight, stools, and vitamins. Type three c diabetes comes with exocrine insufficiency, a low C-peptide, and a lean patient, and because glucagon is lost, titrate insulin cautiously, avoid sulfonylureas, use metformin, and avoid GLP-1 agonists after pancreatitis.

15:12Observe asymptomatic pseudocysts whatever their size, and drain symptomatic, infected, or enlarging ones with a LAMS. A recurring collection means a disconnected duct needing permanent transmural stents or resection. A fibrotic distal bile duct stricture gets a covered metal stent for six to twelve months or surgery. Splenic vein thrombosis with bleeding gastric varices is cured by splenectomy, and high-amylase ascites or effusion means a duct leak. Embolize a pseudoaneurysm before any drainage, and screen for cancer only in PRSS1.

15:47Episode three is autoimmune pancreatitis: the two types, the cancer it imitates, and the steroids that treat it.

15:56For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode two of five of chapter twenty-six, and I'll see you in the next one.